TRCT
RXRX icon

Tower Research Capital (TRC)’s Recursion Pharmaceuticals RXRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$122K Buy
39,862
+34,293
+616% +$133K ﹤0.01% 2032
2025
Q4 		$22.8K Sell
5,569
-156,102
-97% -$773K ﹤0.01% 2999
2025
Q3 		$789K Buy
161,671
+84,501
+109% +$444K 0.02% 613
2025
Q2 		$390K Sell
77,170
-23,835
-24% -$117K 0.01% 1188
2025
Q1 		$534K Buy
101,005
+95,578
+1,761% +$697K 0.02% 799
2024
Q4 		$36.7K Buy
5,427
+616
+13% +$4.14K ﹤0.01% 2755
2024
Q3 		$31.7K Sell
4,811
-29,252
-86% -$210K ﹤0.01% 2972
2024
Q2 		$255K Buy
34,063
+19,585
+135% +$171K ﹤0.01% 1887
2024
Q1 		$144K Buy
14,478
+874
+6% +$9.73K ﹤0.01% 1621
2023
Q4 		$134K Buy
13,604
+5,314
+64% +$37.9K ﹤0.01% 2411
2023
Q3 		$63.4K Sell
8,290
-10,228
-55% -$102K ﹤0.01% 2351
2023
Q2 		$138K Buy
18,518
+3,574
+24% +$25K ﹤0.01% 1817
2023
Q1 		$100K Buy
14,944
+12,645
+550% +$100K ﹤0.01% 1874
2022
Q4 		$18K Sell
2,299
-13,112
-85% -$129K ﹤0.01% 3232
2022
Q3 		$164K Buy
15,411
+10,649
+224% +$108K ﹤0.01% 2117
2022
Q2 		$39K Buy
4,762
+1,824
+62% +$12.2K ﹤0.01% 3127
2022
Q1 		$21K Sell
2,938
-1,171
-28% -$12.4K ﹤0.01% 3494
2021
Q4 		$70K Buy
4,109
+3,528
+607% +$66.4K ﹤0.01% 2491
2021
Q3 		$14K Sell
581
-1,931
-77% -$54.7K ﹤0.01% 4040
2021
Q2 		$91K Buy
+2,512
New +$74.3K ﹤0.01% 2506

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tower Research Capital (TRC)'s RXRX Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Recursion Pharmaceuticals (RXRX) stake by 616% in Q1 2026, buying an estimated $133K and bringing the position to 39,862 shares worth $122K. The position accounts for ﹤0.01% of the portfolio, ranked #2032.

Tower Research Capital (TRC) first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $789K in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Tower Research Capital (TRC) held 39,862 shares of Recursion Pharmaceuticals worth $122K as of Q1 2026.
  • Tower Research Capital (TRC) bought 34,293 Recursion Pharmaceuticals shares in Q1 2026, an estimated $133K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2032 holding.
  • Tower Research Capital (TRC) first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s Recursion Pharmaceuticals position peaked at $789K in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.